McLeod D T, Capewell S J, Law J, MacLaren W, Seaton A
Thorax. 1985 Nov;40(11):840-5. doi: 10.1136/thx.40.11.840.
Seventeen subjects with chronic severe asthma completed a 48 week prospective, double blind study with crossover of treatment at 24 weeks, in which triamcinolone acetonide 80 mg intramuscularly every four weeks was compared with oral prednisolone 10 mg daily. Spirometry, twice daily measurements of peak expiratory flow rate, and self assessment of asthma symptom scores showed significant improvement during triamcinolone treatment; less extra prednisolone was required and there was significant weight loss. Two patients withdrew, one because of dissatisfaction with prednisolone and one because of side effects while taking triamcinolone. Three were withdrawn, one with proximal muscle weakness and two because of intercurrent illness. Adrenal suppression, bruising, and hirsuitism were worse with triamcinolone, other side effects being comparable. On completion of the study 16 of the 17 patients opted to continue taking triamcinolone acetonide. This treatment is an important addition to the therapeutic options available for chronic severe asthma.
17名慢性重度哮喘患者完成了一项为期48周的前瞻性双盲研究，在24周时进行治疗交叉，将每四周肌肉注射80毫克曲安奈德与每日口服10毫克泼尼松龙进行比较。肺功能测定、每日两次的呼气峰值流速测量以及哮喘症状评分的自我评估显示，在曲安奈德治疗期间有显著改善；所需额外泼尼松龙较少，且体重显著减轻。两名患者退出，一名因对泼尼松龙不满意，一名因服用曲安奈德出现副作用。三名患者被退出研究，一名患有近端肌无力，两名因并发疾病。曲安奈德导致的肾上腺抑制、瘀伤和多毛症更严重，其他副作用相当。研究结束时，17名患者中有16名选择继续服用曲安奈德。这种治疗方法是慢性重度哮喘现有治疗选择中的一项重要补充。
